Outlook Therapeutics reported enrollment delays for a clinical trial of Lytenava (bevacizumab-vikg), its investigational formulation of bevacizumab for use in retinal treatments.

The NORSE 2 trial is continuing to screen and treat patients but is subject to additional COVID-19 safety protocols that have caused some sites to temporarily shut down and enrollment to slow.